Induction Treatments with and Without Addition of One Dose Anthracycline to All-trans Retinoid Acid and Arsenic in Pediatric Non-high-risk Acute Promyelocytic Leukemia: Study Protocol for a Randomized Controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2024 Dec 19

PMID 39695871

Authors

Zhong Fan

Xiu-Ya Huang

Dan-Ping Huang

Jie-Si Luo

Jia-Yin Su

Xiao-Li Zhang

Yu Li

Li-Na Wang

Cong Liang

Xue-Qun Luo

Li-Bin Huang

Yan-Lai Tang

Affiliations

Soon will be listed here.

Abstract

Background: The treatment of all-trans retinoic acid (ATRA) and arsenical agent has revolutionarily improved the prognosis of acute promyelocytic leukemia (APL) both in adults and children. Nevertheless, coagulation disorder and differentiation syndrome (DS) are the main causes of early death in APL patients. Early chemotherapy to reduce leukocytes during induction is an important measure to reduce complications and mortality. However, the incidence of hyperleukocytosis (WBC > 10 × 10/L) was significantly higher in pediatric patients without chemotherapy than in adults. Although ATRA plus arsenic is the standard therapy for non-high-risk adult patients, it remains controversial whether chemotherapy is necessary for induction therapy in pediatric APL.

Methods: This study was designed as a multicenter randomized controlled trial. Children with APL were randomly assigned into experimental group (ATRA-RIF plus chemotherapy) and control group (ATRA-RIF). The experimental group was treated with ATRA-RIF plus chemotherapy for induction, while the control group was treated with ATRA-RIF alone. In addition, both groups received the same regimen of ATRA-RIF plus chemotherapy for consolidation and maintenance.

Discussion: This trial aims to compare the efficacy of ATRA-RIF plus chemotherapy versus ATRA-RIF in pediatric non-high-risk patients with APL to demonstrate that chemotherapy during induction therapy can reduce the incidence of complications such as hyperleukocytosis and DS, thereby reducing mortality.

Trial Registration: Chinese Clinical Trials Registry, ID: ChiCTR2000038877. Registered on October 8, 2020, https://www.chictr.org.cn/showproj.html?proj=60733 . V1.0 date 08/01/2020.

References

Strocchio L, Gurnari C, Santoro N, Putti M, Micalizzi C, Zecca M . Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia. Br J Haematol. 2018; 185(2):360-363. DOI: 10.1111/bjh.15507. View

Creutzig U, Dworzak M, Bochennek K, Faber J, Flotho C, Graf N . First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer. 2017; 64(8). DOI: 10.1002/pbc.26461. View

Kayser S, Schlenk R, Platzbecker U . Management of patients with acute promyelocytic leukemia. Leukemia. 2018; 32(6):1277-1294. DOI: 10.1038/s41375-018-0139-4. View

Cicconi L, Bisegna M, Gurnari C, Fanciullo D, Piciocchi A, Marsili G . Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications. Br J Haematol. 2024; 205(5):1727-1733. DOI: 10.1111/bjh.19759. View

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M . Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2016; 35(6):605-612. DOI: 10.1200/JCO.2016.67.1982. View

Levi M, Toh C, Thachil J, Watson H . Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009; 145(1):24-33. DOI: 10.1111/j.1365-2141.2009.07600.x. View

Zhu H, Huang X . Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. N Engl J Med. 2014; 371(23):2239-41. DOI: 10.1056/NEJMc1412035. View

Kutny M, Gregory Jr J, Feusner J . Treatment of paediatric APL: how does the therapeutic approach differ from adults?. Best Pract Res Clin Haematol. 2014; 27(1):69-78. DOI: 10.1016/j.beha.2014.04.007. View

Zhang L, Zou Y, Chen Y, Guo Y, Yang W, Chen X . Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. BMC Cancer. 2018; 18(1):374. PMC: 5883545. DOI: 10.1186/s12885-018-4280-2. View

10.

Barbui T, Finazzi G, Falanga A . The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 1998; 91(9):3093-102. View

11.

Burnett A, Russell N, Hills R, Bowen D, Kell J, Knapper S . Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(13):1295-305. DOI: 10.1016/S1470-2045(15)00193-X. View

12.

Li H, Zhang Y, Fan S, Li D, Zhang Q, Fu J . Analysis of early death in critically ill patients with acute promyelocytic leukaemia in the HICU. Sci Rep. 2024; 14(1):19987. PMC: 11358486. DOI: 10.1038/s41598-024-71082-2. View

13.

Zhu H, Wu D, Du X, Zhang X, Liu L, Ma J . Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018; 19(7):871-879. DOI: 10.1016/S1470-2045(18)30295-X. View

14.

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S . Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-21. DOI: 10.1056/NEJMoa1300874. View

15.

Sanz M, Fenaux P, Tallman M, Estey E, Lowenberg B, Naoe T . Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019; 133(15):1630-1643. PMC: 6509567. DOI: 10.1182/blood-2019-01-894980. View

16.

Yang M, Wan W, Luo J, Zheng M, Huang K, Yang L . Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. Am J Hematol. 2018; 93(12):1467-1473. PMC: 6282847. DOI: 10.1002/ajh.25271. View

17.

Zheng H, Jiang H, Hu S, Liao N, Shen D, Tian X . Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. J Clin Oncol. 2021; 39(28):3161-3170. PMC: 8478377. DOI: 10.1200/JCO.20.03096. View

18.

Liao L, Chen Y, Huang D, Ye Z, Yang L, Mai H . The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia. Cancer Chemother Pharmacol. 2022; 90(1):45-52. DOI: 10.1007/s00280-022-04449-9. View

19.

Chan A, Tetzlaff J, Gotzsche P, Altman D, Mann H, Berlin J . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013; 346:e7586. PMC: 3541470. DOI: 10.1136/bmj.e7586. View

20.

Sanz M, Lo-Coco F . Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011; 29(5):495-503. DOI: 10.1200/JCO.2010.32.1067. View